Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 361

Sort by

Sort Order Select

Journal Articles

Temporal Dynamics of Bone Marrow Fibrocytes in the Progression of Primary Myelofibrosis

Ivo Veletic, Taghi Manshouri, C. Cameron Yin, Christopher D. Pacheco, Christopher P. Ly, Enes Dasdemir, Evan N. Cohen, Lucia Masarova, Naveen Pemmaraju, Prithviraj Bose, Hagop M. Kantarjian, Zeev Estrov, Patrick K. Reville, Andrew Dunbar, Hussein A. Abbas

Blood (2024) 144 (Supplement 1): 1760.

https://doi.org/10.1182/blood-2024-211966

Published: 2024

Journal Articles

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses

Blood (2023) 142 (Supplement 1): 3267.

https://doi.org/10.1182/blood-2023-188084

Published: 2023

Journal Articles

CLL Cell-Derived Exosomes Impair Immune Function and Normal Hematopoiesis in CLL

Blood (2023) 142 (Supplement 1): 3264.

https://doi.org/10.1182/blood-2023-190712

Published: 2023

Journal Articles

Neoplastic Monocyte-Derived Fibrocytes Induce Bone Marrow Fibrosis in Patients with Primary Myelofibrosis

Ivo Veletic, Taghi Manshouri, Christopher D. Pacheco, C. Cameron Yin, Ying Zhang, Ping Li, Evan N. Cohen, Javier A. Gomez, Jared K. Burks, Srdan Verstovsek, Zeev Estrov

Blood (2023) 142 (Supplement 1): 4516.

https://doi.org/10.1182/blood-2023-191024

Published: 2023

Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data

Blood (2023) 142 (Supplement 1): 4635.

https://doi.org/10.1182/blood-2023-189711

Published: 2023

Journal Articles

Results of a Phase 1/2 Study of Lower Dose CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia after Failure to Hypomethylating Agents

Guillermo Montalban-Bravo, Elias Jabbour, Kelly S. Chien, Gautam Borthakur, Zeev Estrov, Tapan M. Kadia, Farhad Ravandi, Naveen Pemmaraju, Graciela Nogueras-Gonzalez, Heather Schneider, Rosmy John, Meghan Anne Meyer, Hagop M. Kantarjian, Guillermo Garcia-Manero, Xiao Qin DONG

Blood (2023) 142 (Supplement 1): 1873.

https://doi.org/10.1182/blood-2023-178110

Published: 2023

Journal Articles

Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors

Paolo Strati, Ellen J. Schlette, Luisa M. Solis Soto, Daniela E. Duenas, Mariela Sivina, Ekaterina Kim, Michael J. Keating, William G. Wierda, Alessandra Ferrajoli, Hagop Kantarjian, Zeev Estrov, Nitin Jain, Philip A. Thompson, Ignacio I. Wistuba, Jan A. Burger

Blood (2020) 135 (7): 510–513.

https://doi.org/10.1182/blood.2019003570

Published: 2020

Journal Articles

Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy

Philip A. Thompson, Jaya Srivastava, Christine Peterson, Paolo Strati, Jeffrey L. Jorgensen, Tyler Hether, Michael J. Keating, Susan M. O’Brien, Alessandra Ferrajoli, Jan A. Burger, Zeev Estrov, Nitin Jain, William G. Wierda

Blood (2019) 134 (22): 1951–1959.

https://doi.org/10.1182/blood.2019001077

Published: 2019

Includes: Supplemental data

Journal Articles

Myelofibrosis osteoclasts are clonal and functionally impaired

Ivo Veletic, Taghi Manshouri, Asha S. Multani, C. Cameron Yin, Lei Chen, Srdan Verstovsek, Zeev Estrov

Blood (2019) 133 (21): 2320–2324.

https://doi.org/10.1182/blood-2018-10-878926

Published: 2019

Includes: Supplemental data

Journal Articles

Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia

Blood (2019) 133 (10): 1011–1019.

https://doi.org/10.1182/blood-2018-10-879429

Published: 2019

Includes: Supplemental data

Journal Articles

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis

Blood (2018) 132 (16): 1664–1674.

https://doi.org/10.1182/blood-2018-04-846626

Published: 2018

Includes: Supplemental data

Journal Articles

Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide

Blood (2018) 131 (16): 1820–1832.

https://doi.org/10.1182/blood-2017-11-817296

Published: 2018

Includes: Supplemental data

Journal Articles

Characteristics and Survival of Patients with Chronic Phase Myelofibrosis and Elevated Blasts (5-9%), and the Effect of Therapy with JAK2 Inhibitor Ruxolitinib

Lucia Masarova, MD, Prithviraj Bose, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Jorge E. Cortes, MD, Zeev Estrov, MD, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD PhD

Blood (2017) 130 (Supplement 1): 201.

https://doi.org/10.1182/blood.V130.Suppl_1.201.201

Published: 2017

Journal Articles

The Clinical BET Inhibitor, GS-5829, Is Active Against Chronic Lymphocytic Leukemia As Single Agent and in Combination with B-Cell Receptor Signaling Inhibitors

Ekaterina Kim, PhD, Elisa Ten Hacken, PhD, Astrid Clarke, PhD, Michael J. Keating, MD, William G Wierda, MD PhD, Alessandra Ferrajoli, MD, Nitin Jain, MD, Philip A Thompson, MBBS, Zeev Estrov, MD, Jan A. Burger, MD PhD

Blood (2017) 130 (Supplement 1): 3844.

https://doi.org/10.1182/blood.V130.Suppl_1.3844.3844

Published: 2017

Journal Articles

Non-Driver Mutations and Gene Sequence Variants Identified By Targeted Deep Sequencing in Polycythemia Vera and Essential Thrombocythemia

Prajwal Boddu, MD, Alay Mansurov, Lucia Masarova, MD, Prithviraj Bose, MD, Keyur P. Patel, MBBS, PhD, Zeev Estrov, MD, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD PhD

Blood (2017) 130 (Supplement 1): 4183.

https://doi.org/10.1182/blood.V130.Suppl_1.4183.4183

Published: 2017

Journal Articles

Randomized Trial of Ibrutinib Versus Ibrutinib Plus Rituximab (Ib+R) in Patients with Chronic Lymphocytic Leukemia (CLL)

Jan A. Burger, MD PhD, Mariela Sivina, PhD, Alessandra Ferrajoli, MD, Nitin Jain, MD, Ekaterina Kim, PhD, Tapan Kadia, MD, Zeev Estrov, MD, Graciela Nogueras González, Xuelin Huang, PhD, Maro Ohanian, DO, Michael Andreeff, MD PhD, Mathew Thomas, Lynette Alexander-Williams, Hagop M. Kantarjian, MD, Susan M. O'Brien, MD, William G Wierda, MD PhD, Michael J. Keating, MD

Blood (2017) 130 (Supplement 1): 427.

https://doi.org/10.1182/blood.V130.Suppl_1.427.427

Published: 2017

Journal Articles

Myelofibrosis (MF) Leukemic Transformation (LT) in the Era of Ruxolitinib and Genomics: Characteristics and Outcomes

Lorenzo Falchi, MD, Dai Chihara, MDPhD, Prithviraj Bose, MD, Zeev Estrov, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Srdan Verstovsek, MD PhD

Blood (2017) 130 (Supplement 1): 4185.

https://doi.org/10.1182/blood.V130.Suppl_1.4185.4185

Published: 2017

Journal Articles

Combined Venetoclax and Ibrutinib for Patients with Previously Untreated High-Risk CLL, and Relapsed/Refractory CLL: A Phase II Trial

Blood (2017) 130 (Supplement 1): 429.

https://doi.org/10.1182/blood.V130.Suppl_1.429.429

Published: 2017

Journal Articles

Validation of the Myelofibrosis Secondary to PV and ET-Prognostic Model in Patients with Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: MD Anderson Cancer Center

Lucia Masarova, MD, Prithviraj Bose, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Jorge E. Cortes, MD, Zeev Estrov, MD, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD PhD

Blood (2017) 130 (Supplement 1): 4205.

https://doi.org/10.1182/blood.V130.Suppl_1.4205.4205

Published: 2017

Journal Articles

The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial

Mahesh Swaminathan, MD, Hagop M. Kantarjian, MD, Naval Daver, MD, Gautam Borthakur, MD, Maro Ohanian, DO, Tapan Kadia, MD, Courtney D. DiNardo, MDMSc, Nitin Jain, MD, Zeev Estrov, MD, Alessandra Ferrajoli, MD, Guillermo Garcia-Manero, MD, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD, Naveen Pemmaraju, MD, Elias J. Jabbour, MD, William G Wierda, MD PhD, Farhad Ravandi, MBBS, Maria Rhona Pinsoy, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 723.

https://doi.org/10.1182/blood.V130.Suppl_1.723.723

Published: 2017

NARROW

Temporal Dynamics of Bone Marrow Fibrocytes in the Progression of Primary Myelofibrosis

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses

CLL Cell-Derived Exosomes Impair Immune Function and Normal Hematopoiesis in CLL

Neoplastic Monocyte-Derived Fibrocytes Induce Bone Marrow Fibrosis in Patients with Primary Myelofibrosis

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data

Results of a Phase 1/2 Study of Lower Dose CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia after Failure to Hypomethylating Agents

Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors

Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy

Myelofibrosis osteoclasts are clonal and functionally impaired

Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis

Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide

Characteristics and Survival of Patients with Chronic Phase Myelofibrosis and Elevated Blasts (5-9%), and the Effect of Therapy with JAK2 Inhibitor Ruxolitinib

The Clinical BET Inhibitor, GS-5829, Is Active Against Chronic Lymphocytic Leukemia As Single Agent and in Combination with B-Cell Receptor Signaling Inhibitors

Non-Driver Mutations and Gene Sequence Variants Identified By Targeted Deep Sequencing in Polycythemia Vera and Essential Thrombocythemia

Randomized Trial of Ibrutinib Versus Ibrutinib Plus Rituximab (Ib+R) in Patients with Chronic Lymphocytic Leukemia (CLL)

Myelofibrosis (MF) Leukemic Transformation (LT) in the Era of Ruxolitinib and Genomics: Characteristics and Outcomes

Combined Venetoclax and Ibrutinib for Patients with Previously Untreated High-Risk CLL, and Relapsed/Refractory CLL: A Phase II Trial

Validation of the Myelofibrosis Secondary to PV and ET-Prognostic Model in Patients with Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: MD Anderson Cancer Center

The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only